Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab plus chemotherapy vs placebo plus chemotherapy in recurrent platinum-resistant epithelial ovarian cancer with low HER3 expression
2011-005975-17Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in epithelial ovarian cancer (EOC) comparing Pertuzumab plus standard chemotherapy with Placebo plus standard chemotherapy (2 arms). Primary endpoint: Safety and tolerability (Part 1 safety run-in). Started Jun 2012; status: completed.
02
Drugs
pertuzumab
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2011-005975-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005975-17.